HTuO Biosciences, a computational drug discovery biotechnology company, is pleased to announce the addition of Mr. Neil Klompas to the board of directors.
HTuO Biosciences, a biotechnology company developing an innovative molecular simulation platform for drug discovery, is pleased to announce that it has appointed Mr. Neil Klompas as a new member of its Board of Directors.
"I am excited to extend a warm welcome to Neil as he joins HTuO’s Board of Directors," said Dr. Anthony Fejes, Chief Executive Officer of HTuO Biosciences. "Neil brings substantial experience from the pharmaceutical and biotech sectors, and we are thrilled to have him join our mission as we move towards the next stage of growth."
“I am delighted to join HTuO’s Board as the company works to achieve its vision to transform drug discovery and optimization by leveraging new in silico approaches with its proprietary physics engine and machine learning,” remarked Mr. Klompas. “The Company has made great strides in moving the state of the art forward, rethinking computational approaches to solving complex, clinically relevant problems. I look forward to working with the HTuO Board to continue to build value and realize the potential of their platform.”
About Mr. Neil Klompas:
Neil Klompas, CPA, CA, is an experienced executive and board member in the life sciences and healthcare sector. He is currently the President and CEO of Augurex Life Sciences and a board member at NervGen Pharma. Previously, he held the position of President and Chief Operating Officer at Zymeworks Inc. During his tenure, he was responsible for overseeing finance and operations and leading the company through its initial public offering on the NYSE and TSX. Before joining Zymeworks, Mr. Klompas worked at KPMG LLP in their Pharmaceutical, Biotech & Medical Devices M&A Transaction Services practice in Princeton, NJ, as well as in the life sciences assurance practice in Vancouver, Canada. Mr. Klompas has also served as the Board Chair for Ovensa Inc., and as the Chair of the Audit Committee and Special Committee of Liminal Biosciences Inc. until its acquisition in 2023. He holds a BSc in Microbiology & Immunology from the University of British Columbia and is a Chartered Professional Accountant.
About HTuO Biosciences:
HTuO Biosciences is a computational biotechnology company based in Vancouver, Canada. Its mission is to develop advanced molecular simulation software capable of accurately predicting the behaviour of molecules to accelerate drug optimization and expand the range of druggable targets. The core technology, the AtomForge force field, is powered by a novel physics algorithm and utilizes a machine-learning approach to go beyond the limits of current computer-aided drug design tools. To learn more, please visit www.htuobio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240821033887/en/
Contacts
Anthony Fejes
HTuO Biosciences
info@htuobio.com
